by U.S. Medicine
Chemotherapy has long been a component in the first-line treatment for advanced or metastatic colorectal cancer (mCRC). A number of studies in recent years indicate that a subset of patients with specific genetic mutations do not respond well to the recommended 5-fluorouracil-based regimens, such as FOLFOX (5-FU, oxaliplatin, and leucovorin) or FOLFIRI (5-FU, irinotecan, and leucovorin) alone or in combination with other agents.
by U.S. Medicine
When a cure is not possible, longer life is the goal. For patients with multiple myeloma, extending survival is the best available option today, and one of the best ways to achieve that is to receive care through the U.S. Military Health System.
by Jennifer Marquez
As the number of first-line treatments for Waldenström Macroglobulinemia increased, older adults experienced marked improvements in survival Among older patients, median progression-free survival improved from 28.3 months in the early era to 63.3 months in the modern era, according to a new study. Younger patients, on the other hand, showed almost no improvement in median progression-free survival between eras, the authors pointed out.
by Brenda Mooney
A common explanation for the high dropout rate and failure of a substance use disorder program is that patients fear symptoms of opioid withdrawal. A new study suggested that is for good reason, especially since patients who are exposed to full opioid agonists chronically are recommended to already be experiencing moderate withdrawal symptoms before they can get drugs to alleviate the symptoms. That’s why the FDA has approved new alternatives, including auricular stimulators, to help patients through the difficult withdrawal symptoms.
by Brenda Mooney
Authors of a new study strongly urged that patients with schizophrenia or schizoaffective disorder who have a history of suicide attempt and are younger than 59 or obese, should be monitored closely during the COVID-19 pandemic. They warned of the possibility of symptom exacerbation in those patients when they have severe COVID-19 since postmortem examination of brains in that cohort have revealed infection-related impaired brain neurotransmission.
